Treatment of obese PCOS in adolescents and young women.

A novel approach to management of obese PCOS in adolescents and young women:towards tailored interventions devoid of conventional oral- contraceptive therapy. A Multicentric Study. - NILL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/082746

Enrollment

130

Registered

2025-03-19

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E282- Polycystic ovarian syndrome

Interventions

Intervention1: combination pharmacotherapy: metformin and antiandrogens and oral semaglutide for 9 months Control Intervention1: Standard therapy: oral contraceptive pills and spironolactone for 9 mon

Eligibility

Inclusion criteria

Inclusion criteria: Adolescents and young women)

Exclusion criteria

Exclusion criteria: Type 2 diabetes mellitus. Patients with thyroid disease Significant systemic disease . Present/recent history of any acute infection or any chronic infection like tuberculosis, hepatitis B and C. Patient suffering from any malignancy Pregnant patients/Postpartum women Planning for pregnancy within next 1 year Individuals with a history of pancreatitis or conditions that predispose them to pancreatitis, such as gallstone disease

Design outcomes

Primary

Measure	Time frame
To assess the PCOS symptom management (eg.Hirsutism, Menstrual irregularities) and androgen profiling before and after treatment in the two treatment groups.Timepoint: Assessment for the period of three years	—

Secondary

Measure	Time frame
To compare body weight, body composition and Insulin resistance in adolescents before and after treatment in the two groups. Timepoint: Assessment for the period of three years;Investigate Epigenetic Changes before and after treatment in the two treatment arms. Timepoint: Assessment for the period of three years;Compare bone health through DXA, bone turnover markers and HRpQCT before and after treatment in the two treatment groupsTimepoint: Assessment for the period of three years	—

Measure

Time frame

To compare body weight, body composition and Insulin resistance in adolescents before and after treatment in the two groups. Timepoint: Assessment for the period of three years;Investigate Epigenetic Changes before and after treatment in the two treatment arms. Timepoint: Assessment for the period of three years;Compare bone health through DXA, bone turnover markers and HRpQCT before and after treatment in the two treatment groupsTimepoint: Assessment for the period of three years

—

Countries

India

Contacts

Public ContactDr Rama Walia

Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh

ramawalia@rediffmail.com9872997438

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026